Diverticulitis aguda

Case study — Rapid reduction of inflammatory markers in recurrent diverticulitis after CDS (Protocol C, increasing)

Patient: Female, Switzerland, long-standing history of recurrent diverticulitis with biannual flare‑ups over the past 3–4 years; approximately six antibiotic courses in the prior three years.

Presenting episode: Acute inflammatory flare in November 2025. Initial medical contact limited by practitioner unavailability; blood tests were arranged to quantify inflammatory activity. Patient had a prior antibiotic course in August 2025 but elected not to begin further antibiotics in November and instead initiated an oral chlorine dioxide solution (CDS) self‑administered regimen.

Baseline inflammatory marker and timeline

• 13 Nov 2025 (day 0): inflammatory marker = 100

• 17 Nov 2025 (day 4): inflammatory marker = 63

• 20 Nov 2025 (day 7): inflammatory marker = 28

Intervention (self‑administered)

Protocol: Protocol C (increasing).

Preparation and dosing: 3 mL CDS diluted in 100 mL water per dose.

Frequency: 10 doses per day, administered roughly hourly throughout waking hours.

Duration: 7 days. Adherence maintained using an hourly alarm.

Outcome

Over a 7‑day period the patient experienced a clear, continuous decline in the measured inflammatory marker from 100 to 28 — a reduction of 72% from baseline. The trend showed progressive improvement at the mid‑point (day 4) and further decline by day 7. Clinically, the patient reports symptomatic improvement and cessation of antibiotic use for this episode.

Interpretation

This single‑patient case documents a rapid and sustained reduction in a laboratory inflammatory marker during an acute diverticulitis flare, temporally associated with an intensive oral CDS regimen (Protocol C, increasing). The magnitude and tempo of change suggest a clinically meaningful reduction in inflammatory activity over one week. As an uncontrolled, self‑administered case report, causality cannot be established; confounders include natural resolution, prior recent antibiotic exposure (August 2025), and absence of imaging or additional biomarkers.

Limitations

Single patient, no control, limited biomarker set, absence of imaging or stool testing, no standardized clinical severity scoring reported, and self‑reported adherence and outcomes. Safety reporting in this case was limited to the patient’s subjective account; no adverse events were documented.

Conclusions

This report adds to observational data suggesting that an increasing Protocol C CDS regimen may coincide with rapid decreases in systemic inflammatory markers during acute diverticulitis flares. Controlled clinical investigation is required to evaluate efficacy, dose–response, and safety, and to compare CDS with standard antibiotic management or supportive care.

Acknowledgment

Case contributed by the patient, N. Kappenberger, Switzerland.